Kidney Protection Using the RenalGuard® System in Cardiac Surgery

Launched by THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST · Nov 23, 2016

Keywords

ClinConnect Summary

Patients undergoing elective or in-house urgent cardiac surgery will be approached for the KIDNEY study if they fulfil the inclusion criteria. Upon consent pre-operative blood tests will be as per the usual practice. Moreover, 2ml of the serum will be stored for NGAL analysis.

Following the consenting process, patients will be randomised (envelop- based) into either having the RenalGuard® System (Study group) or current medical management (Control group).

Study group:

Patients in the study group will have the RenalGuard® System started in anaesthetic room once the peripheral line and art...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing surgery (elective or in-house urgent)
• • 2. Patient 18 years old and over
• • 3. Patient able to give written consent
• • 4. Patient at risk of developing AKI after cardiac surgery (at least one factor)
• • 1. Diabetics (IDDM or NIDDM) with normal kidney function pre-op
• • 2. Patients with eGFR 20-60
• • 3. Patients undergoing combined cardiac procedures when the CPB time is likely to exceed 120 minutes
• • 4. Patients with Hb of 12.5 g/dl or below
• • 5. Logistic Euroscore of 5 and above
• • 5. Patient not involved with another study
• Exclusion Criteria:
• • 1. Emergency surgery
• • 2. Patient unable to give written consent
• • 3. Patient already dialysis dependent or eGFR \<20
• • 4. Patient partaking in another study
• • 5. Pregnant patients